Drug Type ASO |
Synonyms IOC 001, IOC001 |
Target |
Mechanism IGF-1R modulators(Insulin-like growth factor I receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization ImVax, Inc.Startup |
Active Organization ImVax, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | US | ImVax, Inc.Startup | 07 Nov 2022 |
Ovarian Cancer | Preclinical | US | ImVax, Inc.Startup | 07 Nov 2022 |
Transitional Cell Carcinoma | Preclinical | US | ImVax, Inc.Startup | 07 Nov 2022 |